Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label Trial Evaluating the Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)

NCT04501380 is registered in ClinicalTrials.gov with Bradley Connor as lead sponsor.

NCT NCT04501380
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04501380 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label Trial Evaluating the Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)
Lead sponsor
Bradley Connor
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2020
Completion date
December 30, 2022
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal disease, gastrointestinal infection, small intestinal bacterial overgrowth